Noninvasive discrimination of patients with chronic obstructive pulmonary disease and alpha-1-antitrypsin deficiency using an electronic nose by Hattesohl, Akira & Schmeck, Bernd (Prof. Dr.)
Aus der Klinik fu¨r Innere Medizin, Schwerpunkt Pneumologie
Gescha¨ftsfu¨hrender Direktor: Claus F. Vogelmeier
Fachbereich Medizin der Philipps-Universita¨t Marburg
Noninvasive discrimination of patients with
chronic obstructive pulmonary disease and α1-
antitrypsin deficiency using an electronic nose
Kumulativ-Dissertation
zur Erlangung des Doktorgrades der gesamten
Naturwissenschaften
dem Fachbereich Medizin der Philipps-Universita¨t Marburg
vorgelegt von , Akira D.M. Hattesohl
aus Bremen
Marburg, 2017
Angenommen vom Fachbereich Medizin der Philipps-Universita¨t Marburg am:
4. November 2016
Gedruckt mit Genehmigung des Fachbereichs.
Dekan: Prof. Dr. Helmut Scha¨fer
Referent: Prof. Dr. Bernd Schmeck
1. Korreferentin: Prof. Dr. Annette Becker
Originaldokument gespeichert auf dem Publikationsserver der Philipps-Universita¨t
Marburg http://archiv.ub.uni-marburg.de
Dieses Werk ist unter einer Creative-Commons-Lizenz vom Typ ”Namensnennung -
Nicht kommerziell - Keine Bearbeitungen 4.0 International zuga¨nglich“. Um eine Ko-
pie dieser Lizenz einzusehen, konsultieren Sie http://creativecommons.org/
licenses/by-nc-nd/4.0/ oder wenden Sie sich brieflich an Creative Commons,
Postfach 1866, Mountain View, California, 94042, USA.
Original document saved on the publication server of the Philipps-Universita¨t Mar-
burg http://archiv.ub.uni-marburg.de
This work is licensed under the Creative Commons “Attribution-NonCommercial-
NoDerivatives 4.0 International” License. To view a copy of this license, visit
http://creativecommons.org/licenses/by-nc-nd/4.0/ or send a letter to
Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.
i
“F ifty – fifty, gut – bo¨se, ja – nein, an – aus, Kopf oder Zahl,Mann oder Maus. Ich spiel’ mal Loser, mal Gewinner.Mal spiel’ ich den Normalen und dann den Spinner, doch
ich selbst bleib’ ich immer.”
Blumentopf 1999
Abstract
Objectives
The aim of this thesis was to assess, if human exhaled breath of patients with
chronic obstructive pulmonary disease (COPD) and of patients with α1-antitrypsin
deficiency (AATD), that resembles COPD, can be used for simplified, noninvasive,
and cost-efficient diagnostic purposes using electronic nose technology.
Methods
Exhaled breath condensate and pure exhaled breath of patients with COPD (n =
10), with AATD (n= 23), and healthy controls (n= 10) were sampled and analyzed
by measuring volatile organic compounds (VOCs) via the Cyranose 320 electronic
nose and the BioScout ion mobility spectrometry (IMS) device. Furthermore,
the effect of the α1-antitrypsin augmentation therapy on the exhaled breath (EB)
profile of eleven AATD patients was examined. In addition, EB profiles were
analyzed by linear discriminant analysis (LDA), Mahalanobis distance (MD), and
cross-validation value (CVV) of a k-fold cross-validation.
Results
VOC profiles from AATD patients were significantly different from COPD
patients in exhaled breath condensate (LDA: p < 0.0001, sensitivity of 1.00,
specificity of 1.00, CVV 82.0 %, MD 2.37) and in pure exhaled breath (LDA: p <
0.0001, sensitivity of 1.00, specificity of 1.00, CVV 58.3 %, MD 2.27). Moreover,
VOC profiles of AATD patients before and after augmentation therapy differed
significantly (LDA: p= 0.001, sensitivity of 1.00, specificity of 1.00, CVV 53.3 %,
MD 1.79). The discrimination via the BioScout IMS device supported the results.
Conclusion
It was demonstrated, that an electronic nose and IMS device in combination with
data analysis described in this work can discriminate exhaled breath profiles of
COPD patients from patients with AATD. Additionally, the augmentation therapy
changed the exhaled breath profile of AATD patients. These results suggest, that
electronic noses could be used to improve the noninvasive diagnosis of AATD
and COPD.
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Zusammenfassung
Zielsetzung
Das Ziel dieser Arbeit war es, die Ausatemluft von Patienten mit chronischer
obstruktiver Lungenerkrankung (engl. chronic obstructive pulmonary disease,
COPD) mit der von Patienten mit α1-Antitrypsinmangel (engl. α1-antitrypsin
deficiency, AATD), welcher der COPD sehr a¨hnelt, zu untersuchen. Hierfu¨r
wurde die Ausatemluft mit einer elektronischen Nase gemessen und u¨berpru¨ft,
ob hieraus ein vereinfachter, nicht-invasiver und kostengu¨nstiger diagnostischer
Nutzen gezogen werden kann.
Methoden
Exhaliertes Atemwegskondensat und direkte Ausatemluft wurden von Patienten
mit COPD (n = 10), mit AATD (n = 23) und von gesunden Kontrollen (n = 10)
mittels einer elektronischen Nase (Cyranose 320) und Ionenmobilita¨tsspektrome-
trie (IMS) (Bioscout) untersucht. Der Effekt der AAT-Substitutionstherapie auf
das Ausatemluft-Profil von elf AATD-Patienten wurde ebenfalls analysiert. Die
Profile wurden per linearer Diskriminanzanalyse (LDA), Mahalanobis-Distanz
(MD) und Kreuzvalidierungswert (engl. cross-validation value, CVV) einer k-
fachen Kreuzvalidierung untersucht.
Ergebnisse
Die Profile aus Kondensat-Proben von AATD-Patienten unterschieden sich von
denen von COPD-Patienten (LDA: p < 0,0001, Sensitivita¨t von 1,00, Spezifita¨t
von 1,00, CVV 82,0 %, MD 2,37). Die Profile aus direkter Ausatemluft unter-
schieden sich ebenfalls (LDA: p < 0,0001, Sensitivita¨t von 1,00, Spezifita¨t von
1,00, CVV 58,3 %, MD 2,27). Die gemessenen Ausatemluft-Muster bei AATD-
Patienten vor und nach der Substitutionstherapie vera¨nderten sich statistisch signi-
fikant (LDA: p = 0,001, Sensitivita¨t von 1,00, Spezifita¨t von 1,00, CVV 53,3 %,
MD 1,79). Die Resultate der IMS stu¨tzten diese Ergebnisse.
Schlussfolgerung
Es konnte gezeigt werden, dass die elektronische Nase und IMS in Kombination
mit den hier gezeigten Methoden zur Datenanalyse Ausatemluft von COPD-
Patienten von der Ausatemluft von AATD-Patienten unterscheiden kann. Die
Substitutionstherapie vera¨nderte ebenfalls das Ausatemluft-Profil von AATD-
Patienten. Die elektronische Nase mag somit bei einer nicht-invasiven Diagose
von AATD hilfreich sein.
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1 Introduction
Chronic obstructive pulmonary disease (COPD) is a heterogeneous and life-threatening
disease with an estimated global prevalence of 4.77 % [150]. The diagnosis is complex,
time-consuming, and cost-intensive. A closely related and genetic disease, α1-anti-
trypsin deficiency (AATD), shares similar clinical symptoms [8, 20, 100, 140]. The
diagnosis of AATD is complex as well. For an appropriate therapy it is crucial to
distinguish between these two diseases, which is currently very difficult and elaborate.
As it is known for different forms of cancer to be recognized via odors [99, 120], it is
the aim of the thesis at hand to test the hypothesis, if it is possible to distinguish COPD
from AATD noninvasively and cost-efficiently via odors in exhaled breath (EB) [59].
These differentiating odors can be measured using so-called electronic noses (ENs).
Hence, the following main questions regarding the usage of an EN will be answered:
• Can exhaled breath condensate be used to discriminate between patients with
AATD, with COPD, and healthy controls?
• Can total exhaled breath also be used to distinguish between patients with AATD,
with COPD, and healthy controls?
• Does augmentation therapy has a significant impact on exhaled breath of AATD
patients?
1.1 Chronic obstructive pulmonary disease
COPD is in most cases a preventable disease. It is is characterized by a chronic irritation
of the airways featuring persistent and progressive airflow limitation, that is associated
with an enhanced chronic inflammatory response in the airways and the lung to noxious
agents [51]. COPD comprises chronic obstructive bronchitis and lung emphysema and
is featured by a largely irreversible and progressive obstruction of the lower airways
[51].
The prevalence in Germany was estimated at 7.8 % in 2007 and is predicted to
increase to 11.5 % by 2050 [14]. Additional epidemiological parameters include region,
sex, age, and death toll and have been discussed in detail elsewhere [41, 95, 98, 102].
1.1.1 Etiology
The primary risk factor of COPD is tobacco smoking [51]. Other toxic agents [23, 73,
75, 128, 129, 147], rare genetic factors, like α1-antitrypsin deficiency (see section 1.2)
[68, 124], severe infections, and exacerbations cause or contribute to COPD [51, 101].
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1.1.2 Diagnostics
COPD should be considered in patients with chronic cough or sputum production,
dyspnea and/or a background of exposure to noxious agents [51]. The current clin-
ical diagnosis usually includes pulmonary function testing via spirometry and body
plethysmography to assess airflow obstruction and emphysema [51]. These procedures
are complex, time-consuming, and require the patient to inhale pharmacological agents
[51].
Other parameters, such as exacerbation rate and questionnaires, help to assess the
severity of the disease [19, 47, 51, 71, 72, 111].
COPD can be divided into four severity grades of airflow limitation (I to IV) [51] or
in four risk and symptom groups. These groups are based on the Global Initiative for
Chronic Obstructive Lung Disease (GOLD) severity grade, exacerbation rate, and one
of two questionnaires [51].
1.1.3 Symptoms and pathophysiology
Typically, COPD is accompanied by cough, sputum production, and progressive dys-
pnea as a result of inflammatory processes in the lung [51]. These pulmonary symptoms
usually occur in patients between 40 years and 60 years of age [51]. Pathological
changes affect the airways, lung parenchyma, and pulmonary vasculature, featuring
airflow limitation, air trapping, and pulmonary hypertension [61].
Oxidative stress from exogenous reactive oxygen species (ROS) [123] advance
inflammatory processes [156]. In addition, the activation of inflammatory cells produces
endogenous ROS, which on its part contribute to the progression of COPD [125].
Repeated exposure to ROS causes a chronic inflammatory response, that leads to
structural changes due to permanent damage and recovery [10, 51] resulting in an
impaired gas exchange [148] and a disturbed homeostasis of proteases and protease
inhibitors in the lung, which causes centrilobular emphysema [26, page 231]. In rare
cases this imbalance can be linked to α1-antitrypsin deficiency (see section 1.2).
1.2 α1-antitrypsin deficiency
α1-antitrypsin (AAT) is a systemic serine protease inhibitor (serpin). It is mainly
expressed in the liver [62, 82], but it is also found in other cells [24, 25, 115]. AAT
acts as an acute-phase glycoprotein, primarily as an inhibitor of the proteolytic enzyme
neutrophil elastase [28, 68]. This enzyme is secreted by neutrophil granulocytes
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[145] and it cleaves neighboring tissue in order to let the secreting cells reach sites of
inflammation [12, 13].
However, if not regulated properly, neutrophil elastase may cause damage to the host
tissue [74]. The equilibrium between neutrophil elastase (protease) and AAT (protease
inhibitor) allows the elastase to serve its key function against pathogens, but leaves host
tissue undamaged to the greatest possible extent. This is crucial in lung tissue, as it is
steadily exposed to environmental proinflammatory stimuli.
α1-antitrypsin deficiency (AATD) is a rare co-dominantly inherited genetic disorder.
This disease is characterized by mutations of the AAT gene. Within more than one
hundred characterized mutations of AAT [7] the two major pathological forms are
called S- and Z-type, which are misfolded and less functional [70, 114]. The latter
represents a very severe and the clinically most relevant kind for this disorder [31]. The
physiological form of AAT is called M-type.
The estimated global prevalence for AATD is 0.08 %. Germany has a prevalence of
0.10 % (data taken from [15]). Detailed data from different regions, on sex, and rates
of carriers of a defective gene are given in [15, 29, 40].
1.2.1 Etiology
Besides genetic factors, the same contributing factors for COPD (see section 1.1.1)
apply for AATD [113]. Pulmonary symptoms usually occur about ten years earlier
[69, 84, 143]. Exacerbations go along with increased inflammatory activity in the
airways [60], hence, leading to a raised secretion of neutrophil elastase damaging host
tissue.
1.2.2 Diagnostics
The current diagnosis of α1-antitrypsin deficiency is very complex and cost-intensive.
It can take up to several years until the disorder gets diagnosed properly [20, 140, 142],
due to rare incidence and unspecific symptoms [8, 20, 55, 100, 140].
For this reason, the GOLD guidelines and the World Health Organization (WHO)
recommend, that every COPD patient should be screened for AATD [51], especially
in high prevalence regions, if near relatives are known to suffer from AATD, or when
pulmonary symptoms occur already before midlife [124, 141]. It is assumed, that about
1 % to 2 % of all COPD patients are suffering from AATD [68, 139].
Along with lung function assessment, a diagnosis usually involves serum analysis via
nephelometry for the initial determination of the AAT level, isoelectric focusing (IEF)
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for phenotyping, polymerase chain reaction (PCR) for genotyping, and in rare cases
genome sequencing [8].
1.2.3 Symptoms and pathophysiology
The pulmonary symptoms of AATD are commonly similar to those of COPD and
also asthma [100]. These symptoms may already occur in patients at the age of
30 years to 40 years [68]. The mutated gene usually causes abnormal types of the
AAT protein, which is typically accompanied by low serum levels of the protein [8]:
levels of Z-type diseased individuals reach only about 10 % of healthy ones. Severe
mutations regularly cause the misfolded AAT proteins to polymerize and to thereby
lose their inhibitory ability [39, 68, 86, 87, 88]. This may lead to a specific imbalance
of proteases (neutrophil elastase) and (functional) protease inhibitors. It follows an
improperly controlled proteolytical activity, especially in the lung, which then typically
causes COPD with panlobular emphysema [48, 109]. In this regard, AATD can be
considered a genetic variant of COPD [51].
Since AAT is mainly expressed in liver cells, AATD may cause liver disease [21,
28, 119]. In addition, oxidized and polymers of misfolded AAT proteins seem to have
proinflammatory effects [1, 108, 116].
The key differences between the clinically similar diseases—COPD and AATD—are
summarized in table 1.2.1.
Table 1.2.1: Comparison of COPD and AATD
COPD AATD
Estimated global 4.77 % 0.08 %prevalence
Main cause
noxious gases dysfunctional
and particles AAT protein
mostly preventable genetically inherited
Age at onset of pulmonary 40 to 60 30 to 40symptoms in years
Pathophysiology ROS-induced protease–antiproteasechronic inflammation imbalance
Emphysema centrilobular panlobular
COPD: chronic obstructive pulmonary disease, AATD: α1-antitrypsin deficiency, AAT:
α1-antitrypsin, ROS: reactive oxygen species.
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1.2.4 Treatment
Apart from the standard therapy and management for COPD, a symptomatic and
more specific treatment consists of the administration of the lacking AAT by infusion.
However, the results on therapeutic efficacy across different publications diverge [3, 33,
144, 152]. Generally, there is strong evidence of biochemical effects and safety of the
AAT infusion therapy [32].
1.3 Odors as disease markers
Odors are caused by at least one volatile chemical substance, that can be recognized by
the olfactory system [94] and serve different purposes [97, 112, 149, 132, page 1].
Odors from the body arise as a mixture of odorous chemical compounds, secreted
from numerous cells in various metabolic pathways and can be affected by diet or
diseases [16, 58, 89, 110, 131, 133, 134, 146, 151].
1.3.1 Disorders
Already in the 5th century before the Common Era physicians noticed, that specific
diseases can have an impact on body odors [45, pages 35, 63, 66f., 72, and 110].
The “maple syrup urine disease”, for instance, is named after the characteristic smell
of the urine [103, 122]. Other disorders also have specific odors [38, 49, 91, 104].
Furthermore, the exhaled odors of individuals with cancer differ from that of healthy
controls [99, 120, 138].
1.3.2 Volatile organic compounds
Volatile organic compounds (VOCs) are organic (carbonic) substances, that easily
vaporize, such as ethanol. Although there is no international standardized definition,
VOCs will be defined for the remainder of this thesis as organic compounds, that
evaporate at room temperature or higher.
There are VOCs in human exhaled breath [52, 99, 120], that can be detected and
measured to assess human EB via electronic noses [59] (see section 1.4) or ion mobility
spectrometry (IMS) [79] (see section 3.2).
1.3.3 Exhaled breath condensate
Human exhaled breath (EB) (also pure exhaled breath (PEB)) consists of nitrogen
(≈ 74 %), oxygen (≈ 15 %), carbon dioxide (≈ 4 %) [136, page 107], water vapor
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(≈ 6 %), and organic components [117]. EB also contains certain mixtures of VOCs,
that are influenced by specific diseases or conditions, especially of the lung [92, 154].
Exhaled breath condensate (EBC) is the liquid, that results from cooling exhaled
breath (EB). Thereby, exhaled water vapor including all of its dissolved compounds
condensates. EBC consists of more than 99 % water and different soluble compounds
and provides multiple markers [6, 22, 37, 50, 63, 80, 81, 96, 106, 107, 159]. Collecting
EBC is well established and mostly standardized [63].
Analyzing EBC provides a noninvasive, easily repeatable, simple, and cost-effective
option to assess the lung and the airway lining fluid. Two major advantages are, that
EBC can be easily obtained and stored for later analyses [63]. Due to its harmless
nature, collecting EBC can be performed without impact on the body. This makes the
method suitable for monitoring lung conditions via follow-up examinations, which may
include assessment with an electronic nose.
1.4 Electronic noses
Electronic noses (ENs) are odor detectors, i.e., devices to artificially mimic the mam-
malian olfactory sense. Usually, ENs are able to detect VOCs (see section 1.3.2) via
an array of cross-reactive conducting polymer sensors [85] (see section 3) resulting in
“smellprints”.
These smellprints can be used for computer-aided analysis in regard to comparison
and discrimination of profiles. Those analyses allow the generation of prediction models
to classify new and unknown samples.
It is important to note, that ENs are usually not able to identify single components
out of a complex VOC mixture as they use cross-reactive sensors.
There are no generally accepted recommendations or guidelines for sample taking.
Nevertheless, a commercially successful device, namely the Cyranose 320 (C-320) EN
[67], has been used by other research groups effectively and it turned out to be suitable
and cost-efficient for various applications [34, 35, 36, 43, 59, 83, 135]. Therefore, this
device was used for this work, too.
Several techniques and standard operation procedures (SOPs) were established within
the scope of this work, such as collecting and measuring EBC and standardizing the
assessment of human EB via a specific EN.
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1.5 Ion mobility spectrometry
Besides “classical” ENs, devices using ion mobility spectrometry (IMS) use a funda-
mentally different concept to analyze VOCs. By means of ionization, the IMS is able
to separate molecules on the basis of their physical properties, like mass, size, shape,
and mobility in the gas phase (drift time) [11, 27].
As several analytes can be characterized by the same drift time, a preseparation,
such as gas chromatography (GC) using a multi-capillary column (MCC), for instance,
can improve the sensitivity in terms of qualitative features [11]. Different substances
need different times to pass the MCC (retention time). Hence, this combination (gas
chromatography (GC)/MCC + IMS) provides the characterization of substances by
their retention and drift times. An additional, parallel analysis of VOC samples by
mass spectrometry (MS) associated with gas chromatography (GC-MS) even allows
the identification of single substances in a VOC mixture [11].
The BioScout IMS device [4] is a commercially available instrument. This device is
able to detect discriminating substances for COPD (cyclohexanone) [155], sarcoidosis
[18], and lung cancer [153] in human EB.
One major advantage of the BioScout IMS device is the capability to decompose
complex VOC mixtures down to single molecules. In addition, sampling of breath is
more advanced, as it allows to analyze specific fractions of exhaled breath, e.g., breath
from the lower airways only.
7
8
2 Results
2.1 Exhaled breath condensate
A total of 30 volunteers participated in the EBC experiment, 10 in each group, in
particular, COPD, AATD, and healthy controls (HCs). On average, the HCs (mean
age 30 years) were younger than patients with COPD (mean age 55 years) or AATD
(mean age 66 years). Regarding the %FEV1 (defined as the ratio of the actual forced
expiratory volume in one second (FEV1) and the predicted FEV1), on average the
HCs (105 %) had higher values compared to patients with COPD (51 %) or AATD
(48 %). The proportion of females was higher in HCs (60 %) than in both other groups
(each with 20 %). Only two COPD patients were smoking at the time of sampling
including one pipe smoker. All other AATD and COPD patients and HCs had quit
smoking or were never-smokers. The patient characteristics are summarized in table
2.1.1. The difference in the %FEV1 of AATD and COPD patients reached no statistical
significance (p = 0.08)1. A logistic regression analysis2 showed, that the %FEV1 had
no statistically significant impact (p = 0.46) on the differentiation of COPD and AATD
patients.
Table 2.1.1: Exhaled breath condensate participants
AATD COPD HC
Mean age [a] 55 66 30
(standard deviation) (8) (6) (7)
Number ~ / | 2 / 8 2 / 8 6 / 4
Mean %FEV1 [%] 47.9 51.1 105.2
(standard deviation) (16.6) (10.9) (9.9)
Smoker current / ex 0 / 9 2∗ / 8 0 / 2
%FEV1 is defined as the ratio of the actual FEV1 and the predicted FEV1.
AATD: α1-antitrypsin deficiency, COPD: chronic obstructive pulmonary dis-
ease, HC: healthy control, FEV1: forced expiratory volume in one second,
∗ including 1 pipe smoker.
Data taken from [59].
1Statistical significance is considered with a p-value less than or equal to 0.05.
2A logistic regression is a statistical analysis method for categorical variables.
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Table 2.1.2: Exhaled breath condensate results
Group Linear discriminant analysis
comparison p-value CVV Sensitivity Specificity MD
AATD vs COPD < 0.0001 82.0 % 1.00 1.00 2.37
AATD vs HC < 0.0001 59.5 % 1.00 1.00 2.12
COPD vs HC < 0.0001 80.5 % 1.00 1.00 2.19
Pairwise comparisons and statistical analyses of the linear discriminant analysis
data.
CVV: cross-validation value, MD: Mahalanobis distance, AATD: α1-antitrypsin
deficiency, COPD: chronic obstructive pulmonary disease, HC: healthy control.
Data taken from [59].
The linear discriminant analysis (LDA)3 was able to separate the three groups (see
publication figure 2 (page 29/1261) in reference to the data obtained with the C-320
EN. Each of the groups, namely, AATD, COPD, and HCs, formed a separate cluster
and was clearly distinguishable. The corresponding Mahalanobis distances (MDs)4
were ranging from 2.12 to 2.37: The MD between AATD and COPD was 2.37, the MD
between AATD and HC was 2.12, while the MD between COPD and HC amounted to
2.19. Thus, all MDs were significant. The values of the linear discriminants (LDs) of all
pairwise comparisons showed statistically significant differences (p < 0.0001 in each
case). The sensitivity and the specificity for all comparisons were 1.00. The 100-fold
cross-validations and the corresponding cross-validation values (CVVs)5 were ranging
from 59.5 % to 82.0 %: The CVV of the comparison between AATD and COPD was
82.0 %, the CVV of the comparison between AATD and HC was 59.5 %, while the
CVV of the comparison between COPD and HC amounted to 80.5 %. Summarized
results are displayed in table 2.1.2.
2.2 Pure exhaled breath
A total of 47 volunteers participated in the PEB experiment, 14 AATD patients—
including 11 AATD patients in the infusion group—, 23 COPD patients, and 10 healthy
controls. The patients of the AATD and the AATD infusion group were partially
3The linear discriminant analysis is a statistical method to separate two or more classes.
4The Mahalanobis distance is a distance measure, that takes the distribution and variance of the data
into account. Statistical significance is achieved with a Mahalanobis distance greater than or equal to
1.96. The formula is given on page 28/1260
5The cross-validation value specifies how robust a classification method is, where 100 % is the best
value.
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Table 2.2.1: Pure exhaled breath participants
AATD
AATD COPD HC infusion
Mean age [a] 58 63 51 56
(standard deviation) (8) (8) (7) (9)
Number ~ / | 3 / 7 5 / 18 7 / 3 3 / 8
Mean %FEV1 [%] 41.8 56.5 N/A
44.6
(standard deviation) (18.5) (19.5) (16.6)
Smoker current / ex 0 / 7 2 / 21 0 / 2 0 / 9
%FEV1 is defined as the ratio of the actual FEV1 and the predicted FEV1.
AATD: α1-antitrypsin deficiency, COPD: chronic obstructive pulmonary disease,
HC: healthy control, FEV1: forced expiratory volume in one second, N/A: not
available.
Data taken from [59].
overlapping. On average, all groups were about the same age, while the HCs (51 years)
were slightly younger than COPD patients (63 years) and AATD patients (58 years); the
11 AATD patients in the infusion group were 56 years on average. Not all lung function
parameters were available for the HCs. All other groups had comparable %FEV1 values:
COPD (57 %), AATD (42 %), and AATD infusion (45 %). The fraction of females
in HC (70 %) was higher than in the other groups, COPD (22 %), AATD (30 %), and
AATD infusion (27 %). Only two participants (both COPD patients) were tobacco
smokers at the time of sampling. The characteristics are summarized in table 2.2.1. The
difference in the %FEV1 of AATD and COPD patients reached statistical significance
(p = 0.04). In contrast to the logistic regression analysis, that showed, that the %FEV1
had no statistically significant impact (p = 0.08) regarding the differentiation of COPD
and AATD patients.
Considering the three proband groups—AATD, COPD, and HCs—the LDA was
able to separate them. Here, the variance of the COPD data was larger than in the EBC
experiment (see publication figure 3 (page 30/1262)). Each of the groups formed a
separate cluster, that was clearly distinguishable from the others. The corresponding
MDs satisfied statistical significance: The MD between AATD and COPD was 2.27, the
MD between AATD and HC was 2.67, while the MD between COPD and HC amounted
to 2.28. Thus, the MDs were slightly higher than in the EBC experiment. The values of
the LDs of all pairwise comparisons showed statistically significant differences (each
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Table 2.2.2: Pure exhaled breath results
Group linear discriminant analysis
comparison p-value CVV Sensitivity Specificity MD
AATD vs COPD < 0.0001 58.3 % 1.00 1.00 2.27
AATD vs HC < 0.0001 62.0 % 1.00 1.00 2.67
COPD vs HC < 0.0001 67.6 % 1.00 1.00 2.28
AATD
0.001 53.3 % 1.00 1.00 1.79
pre vs post
Pairwise comparisons and statistical analyses of the linear discriminant analysis
data.
CVV: cross-validation value, MD: Mahalanobis distance, AATD: α1-antitrypsin
deficiency, COPD: chronic obstructive pulmonary disease, HC: healthy control,
pre: before infusion, post: after infusion.
Data taken from [59].
with p < 0.0001). Both, the sensitivity and the specificity for all comparisons were
1.00. The CVVs ranged from 58.3 % to 67.6 %: The CVV of the comparison between
AATD and COPD was 58.3 %, the CVV of the comparison between AATD and HC
was 62.0 %, while the CVV of the comparison between COPD and HC amounted to
67.6 %. See table 2.2.2 for all details.
Evaluating the data of the infusion experiment, the LDA showed a clear separation
between both points in time (each patient was measured before and two hours after
the infusion) (see publication figure 4 (page 30/1262)) with a statistically significant
difference (p = 0.001). Both, the sensitivity and the specificity equaled 1.00. The
MD between the points in time equaled 1.79 and did not reach statistical significance.
The corresponding CVV of 53.3 % was the lowest value by contrast with the other
comparisons. See table 2.2.2 for all details.
2.3 Ion mobility spectrometry
A total of 25 volunteers participated in the IMS experiment, 17 AATD patients—
including 2 AATD patients in the infusion group—and 8 COPD patients (data taken
from [79]).
Evaluating the data of the infusion experiment, IMS chromatograms differed in at
least 22 signals, which had a sum rank (norm U) of 0.000 (see publication table 2 (page
39)).
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Considering the two proband groups—AATD and COPD—the IMS chromatograms
show 5 discriminating signals, which had a sum rank of less than 0.200 (see publication
table 3 (page 42)). A summary of accuracy, sensitivity, specificity, positive and negative
predictive values are given in publication table 4 (page 43).
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3 Discussion
The results presented in chapter 2 indicate, that the C-320 EN in combination with the
described data analysis could distinguish the pattern of VOCs present in the EBC of
patients with an AATD from those with a COPD. Furthermore, it could also distinguish
between the PEB of AATD and COPD patients. Additionally, the electronic nose also
discriminated between patients with either of these diseases from HCs. It might be even
possible, to distinguish between AATD patients before and after their weekly body
weight-adapted infusion with purified human AAT.
The former suggests, that the VOC patterns differ sufficiently between these two
lung diseases to be separated by the C-320 EN, although AATD and COPD share a lot
of clinical features. This is supported by the different underlying pathomechanisms
(compare sections 1.1.3 and 1.2.3). While COPD is driven by first temporary and
then chronic oxidative stress and inflammation, AATD involves a slow but chronic
destruction of lung tissue. Furthermore, the latter indicates, that the augmentation of
AAT by infusion may lead to a change in the VOC profile of AATD patients.
Although it is unclear, whether the condensation of exhaled air affects the detection
of compounds, the results suggest, that EBC contains components that are volatile as
well and, therefore, can be recognized by the C-320 EN. The work carried out in this
thesis is to the author’s knowledge the first published study comparing the smellprints
of EBC samples of patients with AATD and COPD.
Other recent studies show, that neither the subjects’ age nor the sex do have a
statistically significant impact on VOCs detectable by the C-320 EN [43, 118]. See
section 3.1 for further details.
As mentioned in the introduction (see section 1.4), the C-320 EN does not allow
the identification of single components in a complex VOC sample as it uses cross-
reactive sensors. Cross-reactive means here, that both a single sensor responds to
multiple substances and one substance is recognized by several sensors [2]. However,
the response of the sensor array to a certain VOC sample is unique and results in a so-
called “smellprint”, a distinct pattern (profile) of this particular sample [137]. The C-
320 EN is able to detect differences of VOC mixtures, though, the exact differences
can not be determined. This can be done with other devices, that use, for instance, IMS
(this is discussed in section 3.2).
The findings of preceding experiments, where multiple C-320 ENs were tested on
various sampling setups from Leipzig, Mu¨nchen, and Marburg [78], showed, that the
Leipzig setup exhibited a relatively high variance suggesting to be less robust than the
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Mu¨nchen or the Marburg setup to sample human breath. Since, there were no large
differences between the Mu¨nchen and the Marburg setup, the Marburg setup was the
method of choice, as it was established and optimized on site [78].
Furthermore, the results from the preceding experiment also suggest, that the use of
one sampling setup across multiple sites and ENs might be limited, since the variance
of the ENs could exceed the variance of the probands [78]. This could be the result of
slightly different manufacturing, arranging and assembling of single sensors or other
component parts. The devices might yield different results due to different years of
construction or wear and tear of different construction parts.
The relatively high CVVs in both experiments suggest, that the LDA works well on
these kinds of samples. Ideal values of 1.00 are not achieved, but this is not unusual
and shows, that the training models for the prediction differ more or less from the
model built from the original sample set. The smaller CVVs of the PEB analysis
could be attributed to the fact, that these samples had a larger variance than the EBC
samples. A major difference in comparing PEB and EBC is, that the additional steps
of collecting and stabilizing (degassing) the samples have to be performed in the latter
approach. Furthermore, there is a time delay before the sample can be measured due to
the additional steps, in which components of the sample may be degrading.
The results provide evidence, that patients with COPD, severe AATD (Z-type), and
nonsmoking HCs feature different exhaled smellprints, possibly due to different types
of (systemic) inflammation in COPD and AATD patients. This is supported by studies,
that have reported differences in airway inflammation between AATD and COPD.
Comparing the fraction of exhaled nitric oxide (FeNO) in AATD patients to the FeNO
in COPD patients controversial results were found: Higher levels [93] in contrast
to lower levels [90] of FeNO could be measured. Neutrophil chemotactic activity in
sputum appears to be significantly higher in patients with AATD than in patients with
COPD [157]. It is very likely, that the specific defect in AATD has a multitude of
cellular and biochemical consequences, including pulmonary and systemic aspects
[1, 21, 28, 39, 48, 68, 86, 87, 88, 108, 109, 116, 119].
Regarding the data from AATD patients before and after treatment with purified
human AAT, it can be speculated, that the given AAT leads to a change in the VOC
profile. It has been demonstrated, that AAT is directly measurable in the bronchoalveolar
lavage (BAL) fluid after this treatment [64]. Thus, it is likely, that the treatment with
AAT results in modifications of the exhaled VOC profile, and has local and systemic
effects. This is supported by the aforementioned evidence of biological effects of
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the infusion therapy [32]. Though, an inflammatory response after the augmentation,
caused by the administration of foreign human proteins, cannot be excluded [130].
The usage of EBC and the C-320 EN is a cost-effective option to assess the lung, as
it is noninvasive, reproducible, simple, and only needs a few cheap disposable items
while in service.
In conclusion, the C-320 EN combined with the applied analyses could cost-efficiently
detect differences in the smellprints of patients with COPD and AATD. The AAT
infusion therapy seems to change the VOC patterns of affected individuals. The first
suggests, that an electronic nose could be helpful in the assessment of AATD. Hence,
the use of the C-320 EN in the diagnosis of AATD should be evaluated further. Both
methods, assessment of exhaled breath by an EN and by EBC, could be used in larger
trials, as they are noninvasive and sampling is simple to perform.
3.1 Analyses
There are many adequate algorithms for analyzing these types of data, each with
limitations [158]. For example, methods like support vector machines (SVMs) or hidden
Markov models (HMMs) might be favorable to separate groups, but these methods are
often very abstract, difficult to compute, and hard to visualize. Other, unsupervised
methods, such as hierarchical clustering, might include additional parameters to reveal
possible subgroups [42]. Clustering strongly depends on initiation, metric, number of
clusters, etc. At the same time, pitfalls lurk by misapplying certain methods, such as
the usage of orthogonal functions on nonindependent data. Furthermore, the suitability
of the different methods might vary greatly depending on the investigated diseases or
problems. Pioneering work mostly requires simple data models and good visualizability.
Supported by the high values of sensitivity and specificity, the LDA seemed to be a
good choice for the tasks at hand.
However, the important limitation to these discussed studies was the relatively low
number of participants per study group. Small sample sizes can increase the risk
of overfitting, especially if the samples include many variables. Lower CVVs may
also indicate overfitting, but can also be the result of small sample sizes, as single
outliers have increased impact on small sample sets. Therefore, it is crucial, that
the given samples are well-defined, low-noise, and representative. Although, it is
still common to categorize COPD patients spirometrically via airflow limitation, this
grouping might lead to improperly defined classes. Spirometry guidelines demand
deviations of FEV1 up to 150 ml [105]. As spirometric assessment depends on the
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proband’s adherence and form of the day [105], deviation of FEV1 range from 50 ml
to 60 ml, in individual cases more than 100 ml [57]. Annual decline of FEV1 for HCs
(about 30 ml to 40 ml [46]), nonsmoking (about 40 ml to 50 ml) and smoking (about
70 ml) AATD patients [121], and COPD patients (about 30 ml to 80 ml [76]) range
within the maximal permitted deviation. Hence, FEV1 per se might be not precise
enough, to allow a proper classification of probands. Thus, the groups of COPD and
AATD patients could be more heterogeneous than assumed, having led to low CVVs as
a result of lacking well-defined proband groups.
As mentioned earlier, other studies show, that the potential confounders age or sex
have no influence on EB assessed via an EN [43, 118]. At the same time, differences
in the FEV1 between AAT-deficient and COPD patients did not affect results and
conclusions as shown in sections 2.1 and 2.2. Although the differences in the FEV1
between AAT-deficient and COPD patients of the PEB experiment were statistically
significant, the logistic regression revealed, that despite of these differences, the FEV1
had no statistically significant impact.
3.2 Outlook
Sampling could be improved by preconcentrating the samples and reducing possible
contamination sources, like perfumes or other persons, that are present.
Beyond that, building a database containing smellprints of several well-defined patient
groups could help to extend diagnostic purposes and to cover a comprehensive range
of diseases. Especially areas, where diagnoses are difficult to make, were explored
based on this work. These may include neurology and pediatrics, where it can be
very challenging to perform required biopsies [5, 127], and sleep medicine, which
may demand extensive examinations [53, 54]. Furthermore, it was shown, that EN
technology can be integrated into daily clinical practice [30].
Other researchers have built ENs with promising custom-made sensors, for instance,
based on gold nanoparticles [17]. Some of them examined the VOCs in the headspace
of human lung cell line cultures, but also in human breath, and can distinguish between
VOCs of healthy persons and such with cancer. In addition, it is possible to differentiate
between certain types of lung cancer [9, 118]. Furthermore, novel nickel-based chemi-
sensors promise faster recovery rates during purging and less sensitivity to water [56].
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Other techniques
Devices, that extend the EN techniques, provide promising but cost-intensive possibili-
ties for diagnostic examinations. The BIONOTE device, which is also able to analyze
the liquid phase and optical properties, is able to support noninvasively lung cancer
screening [126].
Preliminary results of the comparison of EB from patients with COPD and AATD
with the BioScout IMS device showed, that these two patient groups can also be
differentiated by the IMS (see section 2.3). This way, both these diseases can be
distinguished by single VOCs in EB, that are most likely n-Butanol, Butanone, 2-
Propanol, and 2-Hexanone [79].
A similar technique is proton-transfer-reaction mass spectrometer (PTR-MS). This
method could determine various VOCs in EB associated with liver cirrhosis [44].
Additional knowledge could be gained by determining the composition of the VOC
mixtures and to identify single compounds that differ in certain lung disorders, although
the described methods already allow a distinction without knowing exact details. For
this reason, more detailed data about differentiating compounds could help to gain
important insight into diseases and to investigate further treatment possibilities. With
the help of newer devices and techniques, such as the PTR-MS or IMS coupled with
GC/MS, this is very likely to be solved in the near future.
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ABSTRACT
Background and objective: To compare the volatile
organic compound patterns of patients with COPD
with and without alpha 1-antitrypsin (AAT) deficiency
using electronic nose technology.
Methods: Exhaled breath condensate and pure
exhaled breath of patientswith COPDwith (n = 10) and
without (n = 23) AAT deficiency and healthy controls
(n = 10) were analysed. The effect of human recombi-
nantAATon thevolatileorganic compoundprofileof11
AAT-deficient patients was also examined. Exhaled
breath condensate and pure exhaled breath were
measured using the Cyranose 320. Smell prints were
analysed by linear discriminant analysis (LDA) using
Mahalanobisdistance (MD)andcross-validationvalues
(CVVs).
Results: Smell prints of patients with AAT-deficiency
were different from those with COPD in exhaled
breath condensate (LDA: P < 0.0001, sensitivity of
1.00, specificity of 1.00, CVV 82.0%, MD 2.37) and in
pure exhaled breath (LDA: P < 0.0001, sensitivity of
1.00, specificity of 1.00, CVV 58.3%, MD 2.27). Smell
prints of AAT-deficient patients before and after
human recombinant AAT augmentation were different
(LDA: P = 0.001, sensitivity of 1.00, specificity of 1.00,
CVV 53.3%, MD 1.79).
Conclusions: An electronic nose can detect differ-
ences in smell prints of COPD patients with and with-
out AAT deficiency. Augmentation therapy changes the
volatile organic compoundpattern.Theelectronicnose
may be helpful in the diagnosis of AAT deficiency.
Key words: alpha 1-antitrypsin deficiency, chronic
obstructive pulmonary disease, electronic nose, exhaled
breath, volatile organic compound.
INTRODUCTION
In current clinical practice, COPD is diagnosed and
monitored via symptoms, lung function and the
assessment of responses to inhaled pharmacological
agents. These tests have been standardized and are
generally considered as informative.1 However, the
informationprovidedby these tests is still limited, and
some of them are complex or time-consuming, which
has limited their implementation in medical care.
Alpha 1-antitrypsin (AAT) deficiency is a co-
dominant inherited disorder that is diagnosed by
genotyping and low serum levels of AAT. The costs of
diagnostic procedures are high;2 there is therefore a
need for novel diagnostic methods that are simple,
fast and cost-effective. Within the past decade, cellu-
lar and molecular techniques have been utilized as
options for the diagnosis and monitoring of COPD
and AAT deficiency.3
The analysis of exhaledbreath (EB) has beenused to
non-invasively obtain information about inflamma-
tory processes within the lung. EB contains a complex
mixture of volatile organic compounds (VOCs), which
can be detected using gas chromatography-mass
spectrometry (GC-MS).4 Electronic noses (eNoses)
use a concept essentially different from GC-MS. They
allow online recognition of complexVOCmixtures via
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SUMMARY AT A GLANCE
This study demonstrates that an electronic nose
can distinguish the exhaled breath of patients with
chronic obstructive pulmonary disease with and
without AAT deficiency. Furthermore, it can detect
an acute effect of human recombinant AAT on
exhaled breath.
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composite nanosensor arrays in combination with
learning algorithms.5,6 Each sensor reacts differently to
a certain VOC mixture. The arrays combine discrimi-
nation performance with sensitivity, short response
time and reversible behaviour.5 Data analysis follows a
heuristic approach, allowing the distinction of ‘smell
prints’ from various sources by pattern-recognition
algorithms, thus providing discrimination between
gas mixtures without the identification of (all) indi-
vidual molecular components. The first proof-of-
concept studies in respiratorymedicinedemonstrated
high accuracy in the ex vivo classification of bacterial
infections and promising discrimination of EB
obtained frompatientswith lungcancer andcontrols.7
Furthermore, inflammatory diseases, for example,
asthma and COPD, could be discriminated.3,7
AAT deficiency is known to predispose to COPD
and is symptomatically treated as COPD.1 It is
currently assumed that COPD with or without AAT
deficiency shows different molecular and cellular
characteristics due to the specific deficiency present
in AAT deficiency.8 Thus it may be that the VOC
profile is different in the EB of COPD patients with or
without AAT deficiency. Based on this possibility, it
was the aim of our study to compare smell prints
between COPD patients with confirmed AAT defici-
ency, COPD patients without AAT deficiency and
healthy controls. eNose technology was used to
directly analyze EB, and in addition, the composition
of conventionally obtained exhaled breath conden-
sate (EBC) was analysed to gain an understanding
of the VOC patterns and to differentiate between the
diseases.
METHODS
Two experimental protocols were used. In the first, we
collected EBC samples and analyzed them by eNose;
in the second, the pure exhaled breath (PEB) was col-
lected in a sample bag and these samples were exam-
ined by eNose. In the EBC analysis, we included 10
healthy control subjects, 10 patients with proven AAT
deficiency and 10 patients with COPD in order to
check for hints into the direction of the hypothesis in
a proof-of-concept study. Afterwards, for the PEB
experiment, we again recruited 10 healthy control
subjects, 10 AAT-deficient patients and 23 COPD
patients. Unfortunately, not all subjects were avail-
able for the second approach, thus the groups were
only identical in part.
Study participants
In the first experiment we included patients with
stable COPD (GOLD* stages II and III), with no signs
of exacerbation (Table 1). No patient had received
treatment with oral steroids for at least 4 weeks
before the measurements. Confirmation of AAT defi-
ciency was done by PCR and isoelectric focusing.
Patients with AAT deficiency received a weekly
weight-adapted AAT augmentation therapy; this was
left unchanged during the course of the study. In
patients who had COPD without AAT deficiency, low
AAT levels were ruled out by serum analysis. The
healthy control subjects did not show signs of pul-
monary disorders from lung function or clinical
history. The patients and subjects who participated
in the second experiment were characterized by
analogous procedures.
All participants answered a questionnaire regarding
symptoms, smoking habits, health status, medication
and medical history (Table 1). The study was
approved by the local ethics committee (Marburg
Ethics Committee 59/06) and informed consent was
obtained from each subject.
eNose
For both experiments the Cyranose 320 (C-320)
(Smiths Detection Group Ltd,Watford, UK) was used.
This is a hand-held device capable of detecting
so-called smell prints by analyzing mixtures of VOCs.
The C-320 is equipped with 32 chemical sensors that
respond differently to different VOC mixtures. The
sensors consist of conducting chemiresistors made
from carbon black nanocomposites that change their
resistance in response to VOCs.
One measurement with the C-320 included three
consecutive steps:
1 Baseline: The sensors were exposed to reference
air.
*Global Initiative for Chronic Obstructive Lung Disease.
Table 1 Patient characteristics
AATD COPD Healthy controls
EBC PEB EBC PEB EBC PEB
Mean age in years (standard deviation) 55 (8) 58 (8) 66 (6) 63 (8) 30 (7) 51 (7)
Number / 2/8 3/7 2/8 5/18 6/4 7/3
Mean % FEV1 (standard deviation) 47.9 (16.6) 41.8 (18.5) 53.1 (13.2) 56.5 (19.5) 105.2 (11.1) N/A
Smoker current/ex 0/9 0/7 1†/9 2/21 0/2 0/2
† Pipe.
AATD, alpha 1-antitrypsin deficiency; EBC, exhaled breath condensate; N/A, not available; PEB, pure exhaled breath.
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2 Sampling: The sensors were exposed to sample air.
The changes of sensor resistances compared with
reference air were recorded.
3 Purging: The sensors were refreshed by exposing
them to ambient air.
Measurements
EBC
EBC samples were collected during 10 min of tidal
breathing through a single-use disposable RTube
device (Respiratory Research Inc., Austin, TX, USA). A
nose clip was applied to each subject during EBC
sampling. Before sampling, the collecting tube was
cooled in a refrigerator to a temperature of -20°C.
Immediately after collection, EBC was transferred
into polyethylene tubes (Eppendorf AG, Hamburg,
Germany) that had been washed with double-
deionized water. The collected samples were stored in
reaction tubes at -20°C. Samples were deaerated with
argon (99.9% purity, Linde Gases, Munich, Germany)
and frozen at -80°C.
For themeasurementwith the eNose, 200 mL of EBC
was warmed to 37°C and gently bubbled with argon
gas for 2 min to facilitate evaporation. Ambient air
was used as baseline for 10 s. The snout of the C-320
was held above the surface drawing a sample for 10 s.
PEB
The participants breathed medicinal air (Aer medici-
nalis Linde, Linde Gas Therapeutics GmbH, Unter-
schleißheim, Germany) and exhaled for 10 s at a flow
rate of 100–200 mL/s into a collection bag (Fig. 1).
This medicinal air was also used as reference air for
the 60-s baseline, followed by a 60-s sample draw
from the collection bag. These measurements were
performed in triplicate.
In patients with AAT deficiency, additional PEB
measurements were performed 6 days after augmen-
tation therapy. Human purified AAT (Prolastin,
Talecris Biotherapeutics, Frankfurt, Germany) was
used for augmentation therapy in a dose of 60 mg/kg
body weight.
Data analysis
Linear discriminant analysis (LDA)was used to distin-
guish between groups. A LDA estimates a linear func-
tion that discriminates two groups and represents the
data in a one-dimensional score. In order to improve
comparability, for the PEB experiment repeated mea-
surements from each participant were averaged by
computing arithmetic means and the results norma-
lised toa range from0 to1. For thePEBbeforeandafter
therapy experiment, the data was averaged only. For
the EBC experiment the data was normalised only as
no repeated measurements were done.
As a variance-dependent distancemeasure formul-
tidimensional data the Mahalanobis distance (MD)a
between groupswas used. AMDgreater than 1.96 was
considered significant as this exceeds a 95% confi-
dence level, corresponding to a P-value smaller than
0.05. A MD exceeding 2.58 even satisfies a P-value
smaller 0.01 and corresponds to a confidence level of
99%. The MD was favored over the ‘usual’ Euclidean
distance because the latter does not take into account
the variability of the data.
A k-fold cross-validation was performed in each
run in order to calculate the cross-validation value
(CVV). We used a leave-one-out procedure, in which
one data sample of each group was left out, and
k = n1 · n2, with n1 and n2 being the sample sizes of
groups 1 and 2. The CVV yielded the proportion
of correct predictions in a reduced data set in the
EBC and PEB experiment, as well as for the augmen-
tation data. The values of the LDA were used in
a Mann–Whitney U-test and a Wilcoxon signed-
rank test for paired groups (augmentation data),
respectively.
RESULTS
Patient characteristics can be found in Table 1.
Analysis of EBC by eNose
The LDA is able to separate the three groups as shown
in the canonical plot (Fig. 2). Each of the groups—AAT
deficiency, COPD and healthy controls—forms a
separate cluster and is clearly distinguishable. The
LDA provides excellent performance and statistically
significant differences (P < 0.0001) in the distinction
between groups. Also the CVV performs well with
82.0% between AAT deficiency and COPD (P < 0.0001,
sensitivity of 1.00, specificity of 1.00, these three
parameters refer to the LDA values), 80.5% between
healthy controls and COPD (P < 0.0001, sensitivity of
1.00, specificity of 1.00), and 59.5% comparing
aMD(x, y) = ((x - y)TC-1(x - y))1/2, with x = (x1, . . . , xn), y = (y1, . . . ,
yn) and C-1 as the inverse covariance matrix of the n-dimensional
data.
Figure 1 Schematic design of the pure exhaled breath
sampling. Including bag-in-box system, medical air and
water column for constant expiratory flow.
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healthy controls with AAT deficiency (P < 0.0001, sen-
sitivity of 1.00, specificity of 1.00). The MDs indicates
that the distance between AAT deficiency and COPD
is slightly higher than the other comparisons. Com-
paring the group of AAT deficiency patients with
COPD patients, the distance is 2.37. Comparing AAT
deficiency with healthy controls, the distance is 2.12.
COPD and healthy controls shows aMahalanobis dis-
tance of 2.19.
Analysis of PEB by eNose
Each of the groups, AAT deficiency, COPD and healthy
controls, forms a separate cluster and is clearly distin-
guishable in a three-dimensional plot (Fig. 3).
The LDA provides statistically significant differ-
ences for all comparisons (P < 0.0001). The CVV
between AAT deficiency and COPD is 58.3%
(P < 0.0001, sensitivity of 1.00, specificity of 1.00,
these three parameters refer to the LDA values). The
CVV between AAT-deficient patients and healthy con-
trols is 62.0% (P < 0.0001, sensitivity of 1.00, specific-
ity of 1.00) and 67.6% comparing COPD with healthy
controls (P < 0.0001, sensitivity of 1.00, specificity of
1.00).
MDs in the PEB experiment (2.27–2.67) are slightly
higher than in the EBC experiment (2.12–2.37).The
MD between AAT deficiency and COPD is 2.27. Com-
paring AAT deficiency patients with healthy controls,
the distance is 2.67. When comparing COPD with
healthy controls, the distance is 2.28.
Analysis of PEB before and after therapy
EB of 11 AAT deficiency patients was analysed 6 days
after augmentation and 2–3 h after infusion of the
augmentation therapy with human recombinant AAT.
The MD is 1.79, showing a CVV of 53.3% (Fig. 4,
P = 0.001, sensitivity of 1.00, specificity of 1.00, these
three parameters refer to the LDA values).
DISCUSSION
Our study indicates that an eNose can distinguish
the pattern of VOCs present in the EBC of patients
with AAT deficiency from those with COPD. More-
over, it could also distinguish between the PEB of
AAT deficiency and COPD patients. The eNose also
Figure 2 Canonical plot of Cyranose 320 results from exhaled breath condensate analysis of the three groups. Alpha
1-antitrypsin (AAT)-deficient (H17009) and COPD ( ) patients and healthy controls (HC) () form separate clusters. Cross-
validation indicated good values of discrimination (59.5–82.0%). LD: Value of linear discriminant.
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Figure 3 Canonical plot of Cyranose 320 results from pure exhaled breath analysis of the three groups. Alpha
1-antitrypsin (AAT)-deficient (H17009) and COPD ( ) patients and healthy controls (HC) () form separate clusters. Cross-
validation was in the range (58.3 to 67.6%). LD: Value of linear discriminant.
Figure 4 Linear discriminant analy-
sis (LDA) of the exhaled breath con-
densate data of augmented alpha
1-antitrypsin deficiency patients
before (pre-treatment) and after
augmentation therapy (post-
treatment). The LDA distinguished
between the augmented and
non-augmented alpha 1-antitrypsin
deficiency patients (***P = 0.001).
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discriminated between patients with either disease
from control subjects. It was even possible to distin-
guish between AAT deficiency patients before and
after human recombinant AAT therapy. This suggests
that the VOC patterns differ between the two lung
diseases, although they share common clinical
features. Furthermore, the augmentation with AAT
appears to lead to a change in VOC profile.
EB analysis has been widely used to obtain infor-
mation about inflammatory diseases of the lung. EB
contains hundreds of VOCs, as established using
GC-MS.4 eNoses are a novel approach of VOC detec-
tion via composite nanosensor arrays,5 but in most
cases they do not allow the identification of individual
molecular components.6 In addition to sensor-based
equipment, more recently introduced devices such as
ion mobility spectrometers also provide promising
opportunities for the analysis of VOCs.9
We aimed to determine whether patients with AAT
deficiency could be discriminated by smell prints
from patients with COPD and non-smoking healthy
controls, using either direct analysis of PEB or indirect
analysis by measuring the headspace above EBC
samples. The relatively high CVVs in both experi-
ments suggest that the LDA works well on these kinds
of samples. The smaller CVVs of the PEB analysis
could be attributed to the fact that these samples had
a larger variance than the EBC samples. To our knowl-
edge, this is the first study to compare the EBC smell
prints of COPD with AAT deficiency with those of
COPD only.
The first studies of eNoses in the field of respiratory
medicine indicated high accuracy in the ex vivo clas-
sification of bacterial infection.10,11 Preliminary clini-
cal studies used an eNose for the diagnosis of ear,
nose and throat infections12 as well as for the diagno-
sis of pneumonia.13 Furthermore, EB from patients
with lung cancer exhibited smell prints different from
those of controls14 or patients with a variety of other
lung diseases,15 including COPD.7
With regard to asthma and COPD, a number of
studies with inconsistent results have been pub-
lished. Smell prints of asthma patients could be
discriminated from those of healthy controls16 or non-
smoking COPD patients.3 On the other hand, no sig-
nificant difference between COPD (or AAT deficiency)
patients and non-smoking healthy controls was
found.3,14 In these studies, it was speculated that the
lack of significant differencemight have been due to a
lack of active inflammation in patients with COPD.
However, in general, the presence of airway inflam-
mation, both acute and chronic, is well documented
in COPD patients.17 Another study has shown that the
subjects’ age did not have a significant impact on
VOCs detectable by the eNose.3 In order to rule out
that differences in FEV1 between AAT-deficient and
COPD patients did affect our conclusions, multiple
logistic regression analyses were performed. For both
approaches, EBC and PEB, no significant relationship
was found.
Our results provide evidence that patients with
COPD, severe AAT deficiency (PiZ) and non-smoking
healthy controls exhibit different smell prints, possi-
bly due to different types of (systemic) inflammation.
This is supported by studies that have reported differ-
ences in airway inflammation between AAT defi-
ciency and COPD. Both a higher level18 and a lower
level of fraction of exhaled nitric oxide in AAT-
deficient (PiMZ) subjects compared with COPD
patients have been found.19 Neutrophil chemotactic
activity in sputum appears to be significantly higher
in AAT deficiency (PiZ) than in COPD.20 It is very likely
that the specific defect in AAT deficiency has a multi-
tude of cellular and biochemical consequences,
including the more systemic aspect.
EB comprises a gaseous phase containing VOCs
(such as NO and CO) and a liquid phase, also called
EBC.21 EBC contains aerosol particles, in which a
number of non-volatile molecules have been
identified.22–26 The examination of EBC might be con-
sidered as a non-invasive method for studying the
composition of airway lining fluid.25–28 About 4% of
the EBC in healthy subjects is derived from aero-
solized airway lining fluid.29 Our data suggest that
EBC also contains compounds that are volatile during
degassing, and which can therefore be recognized by
the eNose.
A major difference in comparing the PEB and the
EBC was that an additional step had to be performed
in the latter approach. On the other hand, EBC is stor-
able and can be analysed at a later time, while the PEB
is not storable, as VOCs might get lost. It is unclear
whether the condensation of exhaled air affects the
detection of compounds, and this has to be con-
sidered with regard to targets and methods chosen
for analysis.
From the data on AAT deficiency patients before
and after treatment with purified human AAT, it can
be speculated that AAT leads to a change in VOC
profile. It has been demonstrated that AAT is directly
measurable in the bronchoalveolar lavage fluid after
this treatment;30 it is therefore likely that the treat-
ment with AAT leads to changes in VOC both locally
and systemically. An inflammatory response after
augmentation therapy cannot be excluded because of
the administration of pooled human proteins.
Using a serial test approach for the diagnosis of AAT
deficiency comprising measurement of the serum
level of AAT, isoelectric focusing, and/or PCR for Z
and S alleles, the majority of patients with AAT defi-
ciency can be identified, although there is still an
occasional need for genome sequence analysis.2
However, this diagnostic algorithm is time-
consuming and expensive, and novel procedures are
desirable. They should be simple, accurate, fast and
cost-effective. The use of the eNose in the diagnosis of
AAT deficiency should be evaluated further.
There are important limitations to this study. First,
we investigated a small number of patients and the
training set used here requires validation in a com-
pletely separate cohort. This is in line with the STARD
(standards for the reporting of diagnostic accuracy
studies) statement for the validation of diagnostic
tests.31
In conclusion the eNose Cyranose 320 can detect
differences in smell prints in COPD with or without
AAT deficiency. AAT therapy changes theVOCpattern.
It suggests that an eNose might be helpful in the
eNose discrimination of COPD and AATD 1263
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assessment of AAT deficiency. Both methods, eNose
and EBC, can be used in larger trials as they are
non-invasive and sampling is simple to perform.
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Background
Chronic obstructive lung disease (COPD) is characterized
by a not fully reversible and usually progressive airflow
limitation. The disease is associated with an inflammatory
response of the lungs to noxious particles, mainly cigarette
smoke but also alpha 1-antitrypsin (AAT) deficiency
predisposes to COPD. The usual clinical practice for
diagnosing COPD is following symptoms, performing lung
function and the assessment of responses to inhaled
pharmacological agents. These tests have been standardized
and are generally considered as informative [1]. The tests
are time consuming. Still the quality of the tests is
influenced by experience and may differ depending where
the tests are performed. Further, it is suggested that every
COPD patient is once screened for AAT deficiency
(AATD). Alpha 1-antitrypsin deficiency is a co-dominant
inherited disorder that is diagnosed by low serum levels,
genotyping and phenotyping of AAT.
Usually the serum AAT levels are analyzed first. If the
serum levels are decreased further procedures like genotyp-
ing (with polymerase chain reaction) and phenotyping
(isoelectric focusing) are suggested. The costs of these
diagnostic procedures are high [2] and therefore often not
carried out. Thus, there is a need for novel diagnostic
methods that are simple, fast and cost-effective and maybe
performed bedside. Within the past decade, cellular and
molecular techniques have been utilized as options for the
diagnosis and monitoring of COPD and AAT deficiency [3].
The analysis of exhaled breath (EB) has been used to
noninvasively obtain information about inflammatory pro-
cesses within the lung. EB contains a complex mixture of
volatile organic compounds (VOCs), which can be detected
using gas chromatography–mass spectrometry (GC-MS)
[4]. Electronic noses (eNoses) use a concept essentially
different from GC-MS. In addition, they allow the online
recognition of complex VOC mixtures via composite
nanosensor arrays in combination with learning algorithms
[5, 6]. Another approach is the ion mobility spectroscopy
(IMS), were about 10 ml human breath will be analyzed
directly and without any pre-enrichment. Two different
types of IMS, such coupled to multi-capillary columns
(MCC/IMS) [7–15] and differential mobility spectrometers
[16, 17] were used.
It is currently assumed that COPD with or without AAT
deficiency shows different molecular and cellular character-
istics due to the pathophysiological inflammation present in
AAT deficiency [18]. Thus, it may be that the VOC profile
or smellprint is different in the EB of patients with COPD
R. Koczulla (*) :A. Hattesohl : S. Schmid
Zentrum für Innere Medizin - Pneumologie,
Universitätsklinik Gießen und Marburg,
Standort Marburg, Baldingerstraße,
35043 Marburg, Germany
e-mail: koczulla@med.uni-marburg.de
B. Bödeker
B&S Analytik, BioMedicalCenter,
Otto-Hahn-Str. 15,
44227 Dortmund, Germany
S. Maddula : J. I. Baumbach
Department Microfluidics and Clinical Diagnostics, KIST Europe,
Campus E 71,
66123 Saarbrücken, Germany
Int. J. Ion Mobil. Spec.
DOI 10.1007/s12127-011-0070-0
38
with and without AAT deficiency. Based on this possibility,
it was the aim of our study to compare smellprints between
COPD patients with confirmed AAT deficiency and COPD
patients without AAT deficiency. In another approach also
the influence of AAT augmentation therapy should be
studied. Patients with severe AATD can be treated with
weekly AAT infusions (60 mg/kg body weight). This
therapy regimen is based on studies showing an increase
of AAT lung levels as well as an increase of the
antineutrophil elastase capacity in the epithelial lining fluid
of the lung [1]. Considering this, an influence of the
augmentation on the smellprint of AATD patients seems
Parameter Value
Ionization source 63Ni (555 MBq)
Electric field strength 320 V/cm
Length of drift region 12 cm
Diameter of drift region 15 mm
Length of ionization chamber 15 mm
Shutter opening time 300 μs
Shutter impulse time 100 ms
Drift gas synthetic air (20.5 % O2 (4.5), 79.5 % N2 (5.0))
Drift gas flow 100 ml/min to 300 ml/min
Pressure 101 kPa (ambient pressure)
Multi-capillary column OV-5, polar
Column temperature 40 °C
Table 1 Characteristics of ion
mobility spectrometer (BioScout
2010)
Before augmentation
After augmentation
Fig. 1 IMS chromatograms
before and after AATD
augmentation
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reasonable. Hence, the second aim of the study was to
detect the influence of intravenously given AAT on the
composition of VOCs in EB of AATD patients.
Patients
We included patients with genetically proved severe AATD
(PiZZ genotype). All patients were fasting for at least 2 h.
Patients had to wash out their mouth with water. For
sampling the patients breathed into the device. For every
breath the first expiratory 40 ml were discarded to exclude air
of the oral cavity. The patients breathed until 10 ml of
expiratory air (excluding the oral cavity) were obtained by the
device for sampling. From AATD patients breath samples
were taken twice, directly before and 2 h past their infusion or
augmentation. The numbers of breath samples includedwithin
the two different cases investigated are:
& Before and after substitution: 2
& COPD without AATD: 8
& COPD based on AATD: 17.
Method
The IMS coupled to a multi-capillary column (MCC/IMS)
used was a BioScout (B&S Analytik, Dortmund, Germany)
consisting of the MCC/IMS and a SpiroScout (Ganhorn
Medizin Electronic, Niederlauer, Germany) as sample inlet
unit. The major parameters are summarized elsewhere [8–
12, 19–23]. In this spectrometer a 550 MBq 63Ni β-
radiation source was applied for the ionization of the carrier
gas (air). It was connected to a polar multi-capillary column
(MCC, type OV-5, Multichrom Ltd, Novosibirsk, Russia)
used as the pre-separation unit. In this MCC the analytes
of exhaled breath were sent through 1000 parallel
capillaries, each with an inner diameter of 40 μm and a
film thickness of 200 nm. The total diameter of the
separation column was 3 mm. The relevant MCC parameters
are listed in Table 1.
All subjects were requested to exhale through a
mouth piece connected to a Teflon tube. In each case
end-tidal breath, controlled by a flow sensor, was
collected in a sample loop of 10 ml volume. The
sample air was collected and transferred to the multi-
PRE POST
P_02
PRE POST
P_28
PRE POST
P_41
PRE POST
P_54
PRE POST
P_01
PRE POST
P_07
PRE POST
P_09
Increase:
Decrease: 
Fig. 2 Box-and-whisker plots
related to increasing and de-
creasing signals, before and after
AATD augmentation
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# Area Norm U 1/K0 VS/cm
2 RT/s Nearest analyte
1 P_01 0.000 0.579 1.7 Butanole
2 P_02 0.000 0.550 2.3 Acetone
3 P_07 0.000 0.584 6.0 2-Hexanone
4 P_09 0.000 0.607 6.3 1-Pentanole
5 P_10 0.000 0.569 6.3 1-Butanole
6 P_11 0.000 0.531 6.2 2-Butanone
7 P_12 0.000 0.532 8.6 2-Propanole
8 P_13 0.000 0.578 8.1 2-Hexanone
9 P_14 0.000 0.550 8.6 3-Pentanone
10 P_18 0.000 0.562 17.0 2,5-Dimethylpyrazine
11 P_22 0.000 0.581 23.0 1,2,4-Trimethylbenzene
12 P_28 0.000 1.073 29.4 unknown
13 P_41 0.000 0.608 45.8 unknown
14 P_42 0.000 0.641 51.7 unknown
15 P_44 0.000 0.576 55.6 1,2-Butandiole
16 P_50 0.000 0.598 73.6 unknown
17 P_54 0.000 0.664 77.4 Menthon
18 P_56 0.000 0.735 77.7 unknown
19 P_60 0.000 0.668 84.4 unknown
20 P_62 0.000 0.607 88.5 unknown
21 P_64 0.000 0.616 96.9 unknown
22 P_65 0.000 0.760 95.4 unknown
Table 2 Position of the signals
discriminating AATD before
and after augmentation
Fig. 3 Signals of potential relevance to AATD within the IMS chromatogram
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capillary column for a first chromatographic separation
after reaching 3 times 10ml above the dead volume. Using the
software VOCan 1.4 (B&S Analytik, Dortmund, Germany)
the dead volume was adjustable and fixed in the present case
to 500 ml. The expiration was controlled by a CO2 sensor
element integrated in the SpiroScout and recorded for each
subject.
The peaks were characterized using the software Visual
Now 2.2 (B&S Analytik, Dortmund, Germany), which is
described elsewhere [8, 24–27]. All peaks found are
characterized by their position with drift time (corresponding
1/K0-value), retention time and their concentration repre-
sented by the peak height. For both groups and each of the
peaks a box-and-whisker plot was realized.
A preliminary relation between the peak position and the
identity of the analyte was obtained using the database
BSIMSDB 1.4 (B&S Analytik, Dortmund, Germany), but
parallel measurements using e.g. GC/MSD (gas chroma-
tography/mass selective detector) should be realized with
respect of further confirmation.
Results
We compare two different cases
& IMS chromatograms before and after substitution
& AATD and COPD (without AATD), here we describe
differences between COPD without AATD and COPD
based on AATD.
The IMS chromatograms before and after AATaugmenta-
tion are compared in Fig. 1. The signal with the highest rank
sum is marked by black rectangles. The box-and-whisker
plots related to increasing and decreasing signals, before and
after AAT augmentation are shown in Fig. 2. Totally, 22
different signals were found with rank sum 0.00, the best
value. The positions were reported in Table 2 and shown in
Fig. 3. It should be noted, that because of the preliminary
status of the study and the rather low number of subjects
included so far, the findings need confirmation within a larger
group, but should encourage investigations of exhaled breath
to identify potential biomarkers.
AATD
COPD without AATD
Fig. 4 Signals of AATD and
COPD without AATD within
IMS chromatograms
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Furthermore, the signals P_10, P_11, P_12 and P_13
should be considered also in relation to case two, dealing
with the difference between COPD without AATD and
COPD based on AATD.
Typical IMS chromatograms for case two are shown in
Fig. 4. Some peaks useful for discrimination between
COPD with and without AATD are marked. The box-and-
whisker plots for the five signals with the lowest rank sum
with respect to a potential separation between the two
groups investigated are shown in Fig. 5 and described in
Table 3. In nearly all cases the signal within the group of
COPD without AATD is higher than in AATD.
In the group of COPDwith and without AATD the numbers
of patients were higher than in case before and after
substitution. Therefore, in Table 4 the values of accuracy,
sensitivity, specificity and the positive and negative predictive
value are shown for the five peaks with the rank sum less
than 0.2. In addition, the best thresholds calculated on the
peak height scale are shown. The accuracy is in all cases
higher than 75 %. For peak P_72 the sensitivity was 100 %,
for all other peaks 75 % or higher. The values obtained seem
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Fig. 5 Box-and-whisker plots
of signals potentially separating
AATD and COPD without
AATD
Table 3 Position of the signals discriminating AATD and COPD
without AATD
# Area Norm U 1/K0 VS/cm
2 RT/s Nearest analyte
1 P_72 0.169 0.627 208.1 unknown
2 P_10 0.176 0.569 6.3 1-Butanole
3 P_11 0.184 0.531 6.2 2-Butanone
4 P_12 0.191 0.532 8.6 2-Propanole
5 P_13 0.199 0.578 8.1 2-Hexanone
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to be promising for a preliminary study with just 25 cases.
Generally, the finding needs further confirmation and a higher
number of subjects should be included within the study.
Conclusions
Two different case studies were investigated using MCC/
IMS: before and after AATsubstitution and COPD with and
without AATD. For the first case, from two patients, 22
different signals were found with rank sum 0.00, the best
value to differentiate. In case two, the 17 samples with
AATD and eight with COPD without AATD could be
separated by five peaks.
Our preliminary results demonstrate, that distinct
patterns of a small number of IMS peaks are found to
be useful to separate the classes under investigation.
Therefore, MCC/IMS seems to be a promising method
for the noninvasive identification as shown before for
lung cancer and sarcoidosis patients [19]. But, because of
the comparatively low number of subjects included in the
preliminary study, a higher number should be investigated.
In addition, the relations of the peaks to the analyte need
further confirmation, e.g. using parallel measurements
using GC/MSD.
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C
C-320 Cyranose 320. i, ii, 6, 8, 11, 13, 39
CO2 carbon dioxide. 5
COPD chronic obstructive pulmonary dis-
ease. i, ii, I, 1–5, 7–15
CVV cross-validation value. i, ii, 8, 10,
12–14
E
EB exhaled breath. i, ii, 1, 5, 6, 13–15
EBC exhaled breath condensate. i, ii, 1,
5–9, 11–13
EN electronic nose. i, ii, I, 1, 5, 6, 8, 11–
15, 33
F
FeNO fraction of exhaled nitric oxide. 12
FEV1 forced expiratory volume in one sec-
ond. 7, 9, 13, 14
G
GC gas chromatography. 15, 16
GOLD Global Initiative for Chronic Ob-
structive Lung Disease. 2, 3
H
HC healthy control. i, ii, 1, 5, 7–12, 14
HMM hidden Markov model. 13
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